Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Location status: Recruiting
NCT Number: NCT07224438
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Interested in participating?
Request Info18 year–45 year
Female
Interventional
Phase 2
Boston, Massachusetts, 02114, United States
Location status: Recruiting
Assignment: All study subjects will undergo the same interventions.
Delivery of Interventions:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
Other names: Metastin 45-54
Time frame: 2 weeks
Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration
Time frame: 2 weeks
Mature follicle achievement is defined as evidence of a follicle with maximum diameter ≥18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level.
Contact information is provided by the study sponsor or research team.
Stephanie B. Seminara, MD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01601171
Adnexal Diseases, Anosmia
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT05633966
Endocrine System Diseases, Gonadal Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT06583408
Adnexal Diseases, Anovulation
Jacksonville, Florida, United States
View Trial DetailsNCT03841981
46, XX Disorders of Sex Development, Adnexal Diseases
Madrid, Spain
View Trial Details